Key result
Mitoxantrone and its liposomal formulations demonstrate therapeutic potential in adult acute myeloid leukemia, with liposomal forms offering improved bioavailability and altered toxicity profiles.
Why the study?
Conventional anthracycline regimens in adult AML cause cumulative dose-related cardiotoxicity, prompting the development and evaluation of mitoxantrone and mitoxantrone liposome formulations.
Do mitoxantrone and its liposomal formulation improve outcomes and reduce cardiotoxicity compared to conventional anthracyclines in adult patients with acute myeloid leukemia?
Do mitoxantrone and its liposomal formulation improve outcomes and reduce cardiotoxicity compared to conventional anthracyclines in adult patients with acute myeloid leukemia?
Mitoxantrone and its liposomal formulation present therapeutic potential in adult AML with a focus on reducing anthracycline-induced cardiotoxicity, though clinical evidence for the liposomal form remains limited.
May reduce cardiotoxicity versus anthracyclines in AML induction; leaves open randomized confirmation of liposomal formulations.
Acute myeloid leukemia (AML), a rapidly progressing hematopoietic malignancy, can only be cured hopefully by hematopoietic stem cells transplantation (HSCT). Before HSCT, we usually exert effects by attempting certain regimens to induce these tumor cells to death. Administered in AML patients, the classic “3 + 7” intensive induction regimen including anthracyclines and cytarabine is recommended by guidelines worldwide. However, conventional regimens consist of anthracyclines, a category of drug limited by cumulative, dose-related, progressive myocardial damage and congestive heart failure occurs when its total doses break through the cut-off. Based on this background, mitoxantrone (MIT), an anthraquinone, was developed to a new form to reduce cardiotoxicity. Meanwhile, the nanomedicine, mitoxantrone liposome (Lipo-MIT), was characterized by improved bioavailability and limited toxicity. This drug has great therapeutic potential, but different side effects. We conclude the overall history and development of MIT and Lipo-MIT, which show controversial efficacy of MIT compared to doxorubicin and therapeutic potential of Lipo-MIT. This article reviewed the application of MIT and liposome forms in adult AML patients.
No takes yet. Share an insight, caveat, or question.
Song et al. (2023) conducted a review in Adult Acute Myeloid Leukemia. Mitoxantrone and Mitoxantrone Liposome vs. Daunorubicin and Doxorubicin was evaluated. Mitoxantrone and its liposomal formulations demonstrate therapeutic potential in adult acute myeloid leukemia, with liposomal forms offering improved bioavailability and altered toxicity profiles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: